Aktis Oncology (NASDAQ:AKTS) Given Consensus Rating of “Moderate Buy” by Analysts

Aktis Oncology (NASDAQ:AKTS) has been assigned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $32.00.

Several research firms have commented on AKTS. Weiss Ratings began coverage on shares of Aktis Oncology in a research note on Tuesday, May 12th. They set a “sell (d)” rating on the stock. Leerink Partners began coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 price target on the stock. Bank of America started coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set a “buy” rating and a $34.00 price target on the stock. JPMorgan Chase & Co. started coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, William Blair started coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating on the stock.

Aktis Oncology Price Performance

Shares of Aktis Oncology stock opened at $20.34 on Friday. Aktis Oncology has a 1 year low of $14.72 and a 1 year high of $29.16. The company’s 50 day moving average is $18.67.

Aktis Oncology (NASDAQ:AKTS) last announced its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The business had revenue of $1.87 million for the quarter. Equities research analysts predict that Aktis Oncology will post -1.56 earnings per share for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.